Aligned Genetics, Inc. (KOSDAQ:238120)

Market Cap	47.80B +8.8%
Revenue (ttm)	15.73B -4.7%
Net Income	2.78B -31.6%
EPS	197.09 -30.2%
Shares Out	14.06M
PE Ratio	17.25
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,991
Open	3,190.00
Previous Close	3,075.00
Day's Range	2,980.00 - 3,190.00
52-Week Range	2,930.00 - 6,050.00
Beta	0.34
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Aligned Genetics

Aligned Genetics, Inc. offers cellular imaging and biomolecular analysis solutions worldwide. It also provides molecular diagnostic solutions for rapid results under the Genescale name; and advanced imaging and analysis solutions under the Logos Biosystems name. The company was formerly known as Logos Biosystems, Inc. and changed its name to Aligned Genetics, Inc. in September 2020. Aligned Genetics, Inc. was founded in 2008 and is headquartered in Anyang-Si, South Korea.

• Industry: Laboratory Analytical Instruments
• Founded: 2008
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 238120

Financial Performance

In 2025, Aligned Genetics's revenue was 16.02 billion, an increase of 1.51% compared to the previous year's 15.78 billion. Earnings were 2.91 billion, a decrease of -29.47%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 29, 2026

Data Sources Report a data error